159,148 research outputs found
Enhancing control of schistosomiasis in Niger : assessing morbidity in preschool-aged children, praziquantel treatment efficacy and cost implication for control
No full textBackground: Schistosomiasis, accounted among the neglected tropical diseases (NTDs), represents a major public health problem, particularly in Africa, where more than 95% of all the cases of the world are currently concentrated. The health consequences of Schistosoma infection are considerable. Apart from the known long-term complications of a chronic infection (e.g. portal hypertension, kidney failure, bladder cancer and sterility), schistosomiasis is a debilitating disease leading to anaemia, malnutrition, chronic abdominal and pelvic pain, and diarrhoea.
In 2001, the World Health Assembly (WHA) adopted resolution 54.19, which urged member states to regularly treat at least 75% and up to 100% of all school-aged children at risk of schistosomiasis and other high-risk groups. Moreover, in 2006, the World Health Organization (WHO) launched the “preventive chemotherapy” (PCT) strategy, which relies on the regular administration of anthelminthic drugs to at-risk populations in an integrated manner. Following these international calls for action against NTDs, several African countries, including Niger, launched national control programmes based on PCT with support from partners.
The aims of the present PhD thesis in epidemiology were (i) to assess the morbidity of schistosomiasis in infants and preschool-aged children currently not included in PCT; (ii) to evaluate praziquantel (PZQ) efficacy using different treatment schemes, including a detailed analysis of cost; and (iii) to enhance the control of schistosomiasis and other NTDs in Niger.
Methods and principal finding: First, achievements and remaining challenges of schistosomiasis and soil-transmitted helminthiasis (STH) control in three countries of West Africa (i.e. Burkina Faso, Mali and Niger) that benefited from support of the Schistosomiasis Control Initiative (SCI) have been analysed. In the first 3 years of the control programmes, nearly 13.5 million doses of PZQ have been administrated against schistosomiasis and albendazole against STH with coverage rates varying between 67% and 94%. The PZQ treatments have resulted in a reduction of the prevalence and intensity of Schistosoma infection in sentinel cohorts that were set up to monitor and evaluate the national control programmes. Key challenges these national control programmes are currently facing include the ability to maintain the reduction in morbidity achieved so far and ensuring sustainability.
Second, we assessed morbidity due to schistosomiasis in infants and preschool-aged children who are currently not included in PCT according to WHO guidelines, including risk factors for infection in early childhood. We carried out a cross-sectional epidemiological survey in two villages in Niger: Falmado that is endemic for Schistosoma haematobium only, and Diambala that is a mixed S. haematobium-S. mansoni focus. A total of 282 children were examined (149 girls, 133 boys; average age, 2.6 years) and 224 mothers (average age, 30.1 years). For S. haematobium diagnosis, two urine samples obtained over consecutive days were subjected to a standard filtration method, while the diagnosis of S. mansoni was based on a single stool sample using duplicate Kato-Katz thick smears. Additionally, in Diambala, a pre-tested questionnaire was administered to mothers, which recorded demographic data, recent treatment history with anthelminthic drugs, household sanitation and water supply and bathing practices for their children. Prevalence of egg-patent S. haematobium infection among young children and their mothers was, respectively, 51% and 56% in Falmado, and 61% and 72% in Diambala. The prevalence of S. mansoni infection in Diambala was 44% among children and 52% in mothers. Mixed egg-patent infections of S. haematobium and S. mansoni were revealed in 29% of the children and 37% of the mothers. Results from the questionnaire survey showed that 70% of the children were accompanied by their mothers to schistosomiasis transmission sites before reaching their first birthday, and that three-quarter of the mothers used water directly drawn from the irrigation canals to wash their children.
Third, we evaluated the efficacy and safety of two closely spaced doses of PZQ against S. haematobium and S. mansoni in school-aged children, and characterised re-infection patterns over a 1-year period. The study was carried out in five villages in western Niger: Falmado, Seberi, Diambala, Namarigoungou and Libore. Parasitological examinations consisted of triplicate urine filtrations and triplicate Kato-Katz thick smears at each visit. Two 40 mg/kg oral doses of PZQ were administered 3 weeks apart. Follow-up visits were conducted 6 weeks, 6 months and 12 months after the first dose of PZQ. Adverse events were monitored within 4 hours after dosing by the survey team and 24 hours after treatment using a questionnaire. Our final study cohort comprised 877 children who were infected with either S. haematobium, or S. mansoni, or both species concurrently and received both doses of PZQ. At baseline, the geometric mean (GM) infection intensity of S. haematobium ranged from 3.6 (Diambala) to 30.3 eggs/10 ml of urine (Falmado). The GM infection intensity of S. mansoni ranged from 86.7 (Diambala) to 151.4 eggs/gram of stool (EPG) (Namarigoungou). Adverse events were reported by 33% and 1.5% of the children after the first and second dose of PZQ, respectively. We found cure rates in S. haematobium-infected children 3 weeks after the second dose of PZQ ranging between 49% (Falmado) and 98% (Namarigoungou) and high egg reduction rates (92-100%). Regarding S. mansoni, only moderate cure and egg reduction rates were found (52-59% in Diambala, 55-60% in Namarigoungou).
Fourth, in order to generate additional evidence regarding the safety and efficacy of PZQ for schistosomiasis in infants and preschool-aged children, we pursued a drug efficacy trial using PZQ syrup (Epiquantel®) in children aged below 72 months. The study was carried out between May and August 2010 in three villages. Overall, 243 children infected with S. haematobium and/or S. mansoni were treated with PZQ syrup at a dose of 40 mg/kg after they had received a meal of millet porridge. Children were observed during 4 hours post-treatment and a questionnaire was administered to the mothers the following day to determine adverse events. Follow-up visits consisting of three urine filtrations and triplicate Kato-Katz thick smears were conducted 3 and 6 weeks post-treatment. The proportion of children having presented early adverse events during the 4-hour period post-treatment was 33% and the proportion of adverse events occurring within 24 hours after treatment was 6.2%. No serious adverse events were recorded. The most frequent symptoms were abdominal pains (31%), bloody diarrhoea (16.2%) and sleepiness (15.3%). Before treatment, 165 children were infected with S. haematobium among whom 87% presented a light infection (1-49 eggs/10 ml of urine) and 13% a heavy infection (?50 eggs/10 ml of urine). The overall cure rate against S. haematobium was 86% and 95% after 3 and 6 weeks post-treatment, respectively. Three and 6 months after treatment, the GM egg reduction rate for S. haematobium was 69% and 71%, respectively. With regard to S. mansoni, 96 infected children, were treated with PZQ. Among them, 39% had moderated to heavy infection intensities (?100 EPG). Observed cure rates were 75% and 50%, respectively, 3 and 6 weeks after treatment. The respective GM egg reduction rates were 67% and 19%.
Fifth, in order to help countries in finding viable strategies that are financially acceptable to sustain schistosomiasis control activities, we conducted a cost-effectiveness study comparing a school-based and a community-based mass drug administration strategy for schistosomiasis and STH control in Niger. In 2006, we undertook a survey in four districts to estimate the economic cost per district, per treatment and per Schistosoma infection averted. The study compared the costs of treatment at start-up and in a subsequent year and identified the allocation of costs by activity, input and organization. The total economic cost of the programme, including programme-specific expenditures, national and local government costs and international technical support and programme co-ordination in four study districts, over a 2-year period, was US\$ 456,718, which translates to an economic cost per treatment of US\$ 0.58. The full economic delivery cost of school-based treatment in 2005/2006 was US\$ 0.76, while a somewhat lower cost was observed for community distribution (US\$ 0.46). If only costs to the programme were included, the respective figures were US\$ 0.47 and US\$ 0.41. In the study district over a 2-year period, the average cost per Schistosoma infection averted was US\$ 0.76 for children with one treatment and the cost was US\$ 6.7 for adults.
Conclusion: Sustainability of schistosomiasis and STH control programmes in sub-Saharan Africa remains a grand challenge. Integration with other existing health interventions, particularly those targeting NTDs and strengthening of health systems is a way to ensure continued distribution of anthelminthic drugs and other interventions. At an average cost per treatment of US\$ 0.58, control could be handled by the countries.
A substantive proportion of preschool-aged children had egg-patent Schistosoma infection, inclusive of co-infection with S. haematobium and S. mansoni. Hence, in highly endemic areas, more attention should be paid on preschool-aged children and women of childbearing age, so that they can benefit from PCT, thus, increasing effective coverage of those infected. PZQ syrup is well tolerated in infants and preschool-aged children. The cure and eggs reduction rates were high against S. haematobium infection, but additional studies are warranted to determine the efficacy against S. mansoni.
In school-aged children, PZQ given in two closely spaced doses is efficacious against S. haematobium. However, low egg reduction rate observed against S. mansoni raises concern about mounting PZQ tolerance. ---------- Zusammenfassung:
Hintergrund: Schistosomiasis ist eine vernachlässigte tropische Krankheit, welche ein bedeutendes Problem für die öffentliche Gesundheit darstellt, vor allem in Afrika, wo aktuell mehr als 95% aller weltweit auftretenden Fälle konzentriert sind. Die gesundheitlichen Auswirkungen der Schistosomiasis sind beträchtlich. Abgesehen von den bekannten Langzeit Komplikationen einer chronischen Infektion (wie Pfortaderhochdruck, Leberversagen, Blasenkrebs und Unfruchtbarkeit) ist Schistosomiasis eine kräftezehrende Erkrankung welche zu Anämie, Mangelernährung, chronischen Unterleibsschmerzen sowie Diarrhö führen kann.
Im Mai 2001 wurde an der ‘‘World Health Assembly“ (WHA) die Resolution Nummer 54.19 ins Leben gerufen. Diese Resolution hält Mitgliederstaaten dazu an regelmässig mindestens 75% und bis 100% aller Kinder im Schulalter, welche dem Risiko einer Schistosomen Infektion ausgesetzt sind, sowie andere Gruppen mit hohem Risiko, regelmässig mit Praziquantel zu behandeln. Desweiteren führte die Weltgesundheitsorganisation (WHO) eine Strategie der „präventiven Chemotherapie“ (PCT) ein, welche sich auf eine regelmässige, integrative Verabreichung von Entwurmungsmitteln stützt. Diesen internationalen Aufrufen für die Bekämpfung der Schistosomiasis und anderer vernachlässigter Tropenkrankheiten folgend, lancierten einige afrikanische Länder, einschliesslich Niger, mit Hilfe von Partnern, PCT-basierte, nationale Kontrollprogramme.
Die Ziele dieser Dissertation in Epidemiologie waren (i) die Morbidität durch Schistosomiasis in Klein- und Vorschulkindern, welche derzeit nicht in die PCT Strategie eingeschlossen sind, zu ermessen; (ii) die Wirksamkeit und Verträglichkeit von Praziquantel bei verschiedenen Behandlungsschemata zu evaluieren, einschliesslich einer detaillierten Kostenanalyse; und (iii) die Kontrolle der Schistosomiasis und anderer vernachlässigter Tropenkrankheiten in Niger zu stärken.
Methoden und wichtigste Ergebnisse: Zuerst wurden die bisherigen Leistungen und verbleibenden Herausforderungen der Schistosomiasis und der vom Boden-übertragenen Wurminfektionen in drei Ländern Westafrikas (nämlich Burkina Faso, Mali und Niger), welche von der Unterstützung der “Schistosomiasis Control Initiative“ (SCI) profitierten, analysiert. In den ersten drei Jahren des Kontrollprogramms wurden annähernd 13.5 Millionen Dosen Praziquantel gegen Schistosomiasis, und Alendazole gegen von Boden-übertragenen Wurminfektionen verabreicht mit einer Deckungsrate zwischen 67% und 94%. Die Praziquantel Behandlungen führten zu einer Reduktion der Prävalenz und Intensität von Schistosomen Infektionen in den Beobachtungskohorten welche zur Überwachung und Bewertung der nationalen Kontrollprogramme etabliert worden waren. Die Schlüsselherausvorderungen welchen diese nationalen Kontrollprogramme derzeit gegenüber stehen, sind das Vermögen, diesen Rückgang der Morbidität welcher bisher erreicht wurde beizubehalten sowie die Sicherung der Nachhaltigkeit.
Zweitens ermassen wir die Morbidität von Schistosomiasis in Klein- und Vorschulkindern, welche zur Zeit nicht in der PCT wie von der WHO empfohlen eingeschlossen sind, einschliesslich der Risikofaktoren einer Infektion in der frühen Kindheit. Wir führten eine Querschnittsstudie in zwei Dörfern in Niger durch: Falmado welches endemisch nur für Schistosoma haematobium ist und Diambala welches ein Brennpunkt sowohl für S. haematobium wie auch S. mansoni ist. Insgesamt wurden 282 Kinder (149 Mädchen, 133 Jungen; durchschnittliches Alter: 2.6 Jahre) und 224 Mütter (durchschnittliches Alter: 30.1 Jahre) untersucht. Für die Diagnose von S. haematobium wurden zwei Urinproben an zwei aufeinanderfolgenden Tagen mit der Standard Filtrationsmethode untersucht, während die Diagnose von S. mansoni auf der Untersuchung einer einzelnen Stuhlprobe mittels zweier Kato-Katz Ausstriche beruhte. Desweiteren wurden vorgetestete Fragebögen, welche demographische Daten, kürzliche Behandlungsgeschichten mit Entwurmungsmitteln, die sanitäre Situation des Haushalts und Wasserversorgung sowie Badepraktiken für die Kinder aufnahmen, mit den Müttern in Diambala durchgeführt. Die Prävalenz von Ei-patenten S. haematobium Infektionen bei jungen Kindern und deren Mütter war 51% und 56% in Falmado, sowie 61% und 72% und Diambala. Die Prävalenz von S. mansoni in Diambala war 44% unter den Kindern und 72% unter den Müttern. Gemischte, Ei-patente Infektionen von S. haematobium und S. mansoni zeigten sich in 29% der Kinder und 37% der Mütter. Die Auswertung der Fragebogenstudie zeigte, dass 70% aller Kinder von ihren Müttern zu Schistosomiasis Übertragungsstellen begleitet wurden, bevor sie ein Jahr alt waren und dass drei-Viertel der Mütter Wasser welches sie direkt aus den Bewässerungskanälen bezogen benutzten um ihre Kinder zu waschen.
Drittens evaluierten wir die Wirksamkeit und Sicherheit zweier eng aufeinanderfolgender Dosen Praziquantel gegen S. haematobium und S. mansoni bei Kindern im Schulalter und charaktisierten die Re-infektionsmuster über einen Zeitraum von einem Jahr. Die Studie wurde in den folgenden fünf Dörfern im Westen Nigers durchgeführt: Falmado, Seberi, Diambala, Namarigoungou und Libore. Parasitologische Untersuchungen bestanden aus drei Urinfiltrationen und drei Kato-Katz Ausstrichen bei jedem Besuch. Zwei 40 mg/kg Praziquantel Dosen wurden in einem Abstand von drei Wochen verabreicht. Folgebesuche wurden 6 Wochen, 6 Monate und 12 Monate nach der ersten Praziquantel Dosis durchgeführt. Nebenwirkungen wurden während vier Stunden nach der Medikamentenverabreichung vom Studienteam, und 24 Stunden danach mittels eines Fragebogens überwacht. Unsere letztendliche Studienkohorte bestand aus 877 Kindern die entweder mit S. haematobium oder S. mansoni oder mit beiden parasitären Wurmarten zugleich infiziert waren und beide Dosen Praziquantel erhalten hatten. Bei der Basisstudie reichte der geometrische Mittelwert (GM) der Infektionsintensität von S. haematobium von 3.6 (Diambala) bis 30.3 Eier pro 10 ml Urin (Falmado). Der GM der Infektionsintensität von S. mansoni reichte von 86.7 (Diambala) bis 151.4 Eier pro Gramm Stuhl (EPG) (Namarigoungou). Nebenwirkungen wurden bei 33% bzw. 1.5% der Kinder nach der ersten bzw. zweiten Dosis Praziquantel berichtet. Wir fanden Heilungsraten zwischen 49% (Falmado) und 98% (Namarigoungou) sowie hohe Ei Reduktionsraten (92-100%) bei S. haematobium-infizierten Kindern drei Wochen nach Verabreichung der zweiten Praziquantel Dosis. Für S. mansoni wurden lediglich mittelmässige Heilungs- und Ei Reduktionsraten gefunden (52-59% in Diambala, 55-60% in Namarigoungou).
Viertens führten wir, um weitere Befunde bezüglich der Verträglichkeit und Wirksamkeit von Praziquantel gegen Schistosomiasis bei Klein- und Vorschulkindern zu erhalten, eine Wirksamkeitsstudie mit einem Praziquantel Sirup (Epiquantel® ) bei Kindern mit einem Alter von bis zu 72 Monaten durch. Die Studie wurde zwischen Mai und August 2010 in drei Dörfern in Niger durchgeführt. Insgesamt wurden 243 Kinder welche mit S. haematobium und/oder S. mansoni infiziert waren, mit einer Dosis von 40 mg/kg des Praziquantel Sirups behandelt, nachdem ihnen eine Mahlzeit aus Hirsebrei verabreicht worden war. Nach der Behandlung wurden die Kinder über 4 Stunden beobachtet und am darauffolgenden Tag ein Fragebogen mit den Müttern durchgeführt um Nebenwirkungen zu ermitteln. Folgeuntersuchungen bestehend aus 3 Urinfiltrationen und 3 Kato-Katz Ausstrichen wurden 3 und 6 Wochen nach der Behandlung durchgeführt. Der Anteil Kinder, der frühe Nebenwirkungen während der ersten 4 Stunden nach Behandlung zeigte, lag bei 33% und der Anteil Nebenwirkungen welche innerhalb von 4-24 Stunden nach der Behandlung auftraten bei 6.1%. Es wurden keine ernsten Nebenwirkungen berichtet. Die am häufigsten auftretenden Symptome waren Unterleibsschmerzen (31%) sowie blutiger Durchfall und Schläfrigkeit (16%). Vor der Behandlung waren 166 Kinder mit S. haematobium infiziert, von welchen 87% eine leichte Infektion (1-49 Eier pro 10 ml Urin) und 13% eine schwere Infektion (?50 Eier pro 10 ml Urin) aufwiesen. Die Heilungsrate für S. haematobium betrug im Gesamten 86% drei Wochen, bzw. 95% sechs Wochen nach Behandlung. Der GM der Ei Reduktionsrate für S. haematobium betrug 71% drei, bzw. 77% sechs Wochen nach Behandlung. Gegen S. mansoni wurden 96 infizierte Kinder mit Praziquantel behandelt. Unter diesen hatten 39% eine mittlere bis schwere Infektion (?100 EPG). Die beobachtete Heilungsrate lag bei 75% drei, bzw. 50% sechs Wochen nach Behandlung. Die entsprechenden GM der Ei Reduktionsraten waren 67% und 19%.
Fünftens, um den Ländern dabei zu helfen durchführbare Strategien dafür zu finden die Schistosomiasis Kontrollstrategien langfristig zu gewährleisten, führten wir eine Kosteneffizienzstudie durch in welcher wir eine schulbasierte mit einer gemeindebasierten Massenbehandlungsstrategie gegen die Schistosomiasis und von Boden-übertragener Wurminfektionen verglichen. Unsere Studie wurde im Jahr 2006 durchgeführt in vier Distrikten von Niger um die wirtschaftlichen Kosten pro Distrikt, pro Behandlung und pro abgewendeter Schistosomen Infektion abzuschätzen. In der Studie wurden die Behandlungskosten beim Start und im darauffolgenden Jahr verglichen und die Kostenverteilung auf die Aktivitäten, den Einsatz und die Organisation identifiziert. Die gesamten wirtschaftlichen Kosten des Programms, einschliesslich programmspezifischer Ausgaben, nationaler und lokaler Regierungskosten und internationaler technischer Unterstützung sowie Programmkoordination von vier Distrikten betrugen 456,718 US\$ über einen Zeitraum von zwei Jahren, was einem Kostenpunkt von 0.58 US\$ pro Behandlung entspricht. Die vollen wirtschaftlichen Kosten für eine schulbasierte Behandlung in Jahr 2005/2006 betrugen 0.76 US\$ während für die gemeindebasierte Behandlung etwas niedrigere Kosten beobachtet wurden (0.46 US\$). Wenn man für die jeweiligen Grafiken ausschliesslich die Kosten des Programms berücksichtigt, handelt es sich um 0.47 US\$ bzw. 0.41US\$. Die durchschnittlichen Kosten pro abgewandter Schistosomen Infektion im Studiengebiet über den Zeitraum von zwei Jahren betrugen 0.76 US\$ für Kinder mit einer Behandlung und 6.7 US\$ für Erwachsene.
Schlussfolgerungen: Die Nachhaltigkeit von Kontrollprogrammen gegen die Schistosomiasis und anderer vernachlässigter Tropenkrankeiten in Subsahara-Afrika bleibt eine gewaltige Herausforderung. Die Eingliederung in andere Gesundheitsinterventionen, vor allem jener welche auf vernachlässigte Tropenkrankheiten und die Stärkung von Gesundheitssystemen abzielen, stellt einen Weg dar, um die kontinuierliche Verteilung von Entwurmungsmedikamenten und anderer Interventionen sicher zu stellen. Wir spekulieren, dass die durchschnittlichen Kosten von 0.58 US\$ pro Behandlung von den Ländern gehandhabt werden können.
Ein bedeutender Anteil Vorschulkinder hatte eine Ei-patente Schistosomen Infektion, inklusive Co-Infektion zwischen S. haematobium und S. mansoni. Daher sollte in hochendemischen Gebieten Vorschulkindern und Frauen im gebährfähigen Alter mehr Aufmerksamkeit geschenkt werden, damit sie von der PCT profitieren und so die effektive Abdeckung der Infizierten erhöht wird. Praziquantel Sirup wird von Klein- und Vorschulkindern gut vertragen. Gute Heilungsraten und hohe Ei Reduktionsraten wurden bei der S. haematobium gefunden, doch weitere Studien sind angebracht um die Wirksamkeit gegen S. mansoni zu bestimmen.
Bei Kindern im Schulalter ist Praziquantel in zwei eng beieinanderliegenden Dosen verabreicht, wirksam gegen S. haematobium. Jedoch erweckt die niedrige Ei
TEMBUNG GARBA WONTEN ING RUBRIK MACAPAT KALAWARTI DJAKA LODANG WEDALAN WULAN JANUARI-JUNI 2013
No full textPanaliten menika gadhah ancas kangge ngandharaken tembung garba wonten ing rubrik macapat kalawarti Djaka Lodang wedalan wulan Januari-Juni 2013. Tembung garba ingkang dipuntliti gayut kaliyan wujudipun garba, pandhapukipun tembung garba, saha tegesipun tembung garba.
Panaliten menika mujudaken panaliten deskriptif, inggih menika ngandharaken tembung garba wonten ing rubrik macapat kalawarti Djaka Lodang wedalan wulan Januari-Juni 2013. Data panaliten menika awujud tembung ingkang kalebet tembung garba, sumbering data ngginakaken kalawarti Djaka Lodang inggih menika perangan rubrik macapat kanthi 26 kempalan macapat utawi 26 edisi. Caranipun ngempalaken data inggih menika kanthi teknik maos saha nyerat. Pirantining panaliten inggih menika human instrument saha tabel analisis data ingkang dipunbiyantu kaliyan kertu data. Caranipun nganalisis data inggih menika kanthi cara deskriptif, ingkang kanthi lampahan identifikasi, tabulasi, reduksi, saha inferensi. Caranipun ngesahaken data kanthi cara validitas triangulasi teori saha validitas semantis, sarta reliabilitas intrarater saha reliabilitas interatter. Reliabilitas intrarater ngginakaken lampahan Cek Ricek, wondene reliabilitas interater kanthi cara Expert Judgement.
Asilipun panaliten menika ngandharaken wujudipun garba, pandhapukipun tembung garba, sarta tegesipun tembung garba wonten ing rubrik macapat kalawarti Djaka Lodang. Wujuding garba ingkang dipunpanggihaken wonten ing panaliten menika wonten kalih jinis, inggih menika tembung garba lumrah saha garba sutra ye. Manawi dipuntingali saking proses morfofonemik-ipun, tembung garba lumrah wonten wolung jinis proses morfofonemik sandi, inggih menika /a/ + /a/ = /a/, /a/ + /i/ = /e/, /a/ + /e/ = /e/, /a/ + /o/ = /o/, /i/ + /i/ = /e/, /u/ + /i/ = /e/, /e/ + /i/ = /e/ sarta /a/+/a/=/e/. Proses morfofonemik elipsis wonten pitung jinis, inggih menika elipsis /s/, (tan), /r/, /n/, (ha), /e/, sarta /a/. Wondene jinis garba sutra ye proses morfofonemik sandi wonten satunggal jinis, inggih menika /i/ + /a/ = (ya) . Pandhapukipun tembung garba wonten panaliten menika dipunperang dados kalih, inggih menika tembung garba ingkang sami kaliyan jinis tembung pandhapukipun saha ingkang beda kaliyan tembung pandhapukipun. Tegesipun tembung garba wonten panaliten menika dipunperang dados kalih jinis, inggih menika tegesipun tembung garba ingkang sami saha ingkang beda kaliyan teges tembung pandhapukipun
A preliminary re-assessment of Garba III at Melka Kunture, a Middle Stone Age site with archaic Homo sapiens remains
No full textGarba III is one of the many sites of Melka Kunture, in the middle Awash Valley, where the archaeological record starts a c. 1.7 Ma. It was excavated in the Seventies of last century under the direction of Francis Hours, who was only able to publish a few preliminary reports before his untimely death. Hours recognized a large MSA assemblage with some small handaxes. An age close to 150ka was suggested. Three skull fragments related to Homo sapiens were also discovered. Notwithstanding the lack of detailed analysis and of published information, Garba III has ever since been quoted in the scientific literature. In 2011 the original site was re-located, geological trenches were dug, and the stratigraphic sequence was documented into detail. The result of the geomorphological investigation and of U-series dating will be presented at the congress. The study of the large lithic collection, now at the National Museum of Ethiopia, is under way. Except for a few flint and basalt artefacts, obsidian was invariably used in the analysed sample. Small obsidian pebbles were knapped by bipolar percussion, but larger blocks were also available, and there is some evidence of discoid and Levallois reduction sequences. Triangular or quadrangular flakes were produced, generally less than 30mm long, and never more than 60mm in length. Formal tools include scrapers, endscrapers, denticulates and points with a thick triangular section. Pièces esquillées are frequent, mostly on the ventral face, and occur in association with other retouched edges. In a preliminary palaeontological analysis, Denis Geraads identified a hippo of very large size, a large giraffe, at least five bovid species, including a bovine, two alcelaphines (?Damaliscus and Connochaetes), a reduncine (kob), and an antilopine (cf. Gazella), as well as a few Equus remains
Appropriate Similarity Measures for Author Cocitation Analysis
No full textWe provide a number of new insights into the methodological discussion about author cocitation analysis. We first argue that the use of the Pearson correlation for measuring the similarity between authors’ cocitation profiles is not very satisfactory. We then discuss what kind of similarity measures may be used as an alternative to the Pearson correlation. We consider three similarity measures in particular. One is the well-known cosine. The other two similarity measures have not been used before in the bibliometric literature. Finally, we show by means of an example that our findings have a high practical relevance.information science;Pearson correlation;cosine;similarity measure;author cocitation analysis
The relationship between illness perception and worsening of interstitial cystitis/painful bladder syndrome symptoms: A cross‐sectional study
No full textObjective: To evaluate disease perception in a cohort of patients with interstitial cystitis/painful bladder syndrome (IC/PBS) using the Brief Illness Perception-Questionnaire (BIP-Q) and to evaluate how this might relate to disease severity. Materials and Methods: The study is a cross-sectional survey amongst members of Bladder Health UK who had previously received a clinical diagnosis of IC/PBS. A hyperlink containing the questionnaire was sent to the patient group's website and interested members accessed and completed the survey. Participants' inclusion was based on a prior clinical diagnosis of IC/PBS, current O'Leary Sant scores supportive of the diagnosis, and age between 18 and 80. A sample size of 171 was used in the study. The Brief Illness Perception Questionnaire (BIP-Q) and the O'Leary/Sant symptoms and problem indices questionnaire were used to collect data. A multivariable logistic regression analysis was used to test the relationship between items of BIP-Q and severity of IC/PBS. Content analysis was used for the causal domain and subsequently analysed as percentages. Results: Six hundred and one members accessed the questionnaire of whom 159 returned completed questionnaires. One hundred and twenty-two of 159 (≥75%) respondents believe that their illness will continue indefinitely. The majority of the respondents indicated that IC/PBS had a negative impact on their daily lives, caused them worry and made them emotionally unstable. Of the 8 BIP-Q items, those most predictive of disease severity were (adjusted odd ratio and confidence intervals): consequence 0.094 (0.023–0.386); treatment control 2.702 (1.256–5.812); identity 0.141 (0.033–0.600); concern 9.363 (1.521–57.632). Conclusions: Our findings show that IC/PBS negatively impacts participant's quality of life and emotional wellbeing. Higher expectation for treatment benefit and increasing levels of patient concern are predictive for severity of IC/PBS.</p
The architecture and chemistry of a dug-out : the Dufuna canoe in ethno-archaeological perspective
No full textThis research work emanated from a joint research project between the Johann-Wolfgang Goethe-University Frankfurt am Main, Germany and the University of Maiduguri, Nigeria; as outlined in the Bilateral Agreement of July 21st 1988.1 The research program is interdisciplinary in nature involving these areas: Archaeology, Geography, Linguistics and Historical Ethnology; all under the general theme of West African Savannah. Considerable research work has already been carried out in these areas by German explorers and scholars dating back to the mid-nineteenth century. The project is funded by the German Research Foundation. The present paper addresses itself purely to one and very important aspect of an archaeological campaign undertaken in the Chad Region of Nigeria in late 1990/1991 season. In consequence to reconnaissance survey and excavation conducted at a site called Gajiganna, abundant lithic materials were noticed and collected. The crucial question one poses to the site which lacks physical outcrops in and within the precinct of the settlement are, what could have been the source of the raw materials at the site? Were they transported from somewhere to the site? If so, why was it necessary for the materials to be brought to this site? These and other related questions posed a serious commodity problem for most sites in Borno with lithic materials
Medical-grade manuka honey inhibits mast cell degranulation by downregulating Protein Kinase-B (Akt) Phosphorylation: Potential role as intravesical agent in the treatment of interstitial cystitis/bladder pain syndrome.
No full textBackground: mast cells numbers and activity are significantly elevated in several inflammatory conditions including interstitial cystitis (IC/BPS). This condition is associated with the release of neuroactive substances, e.g. substance P (SP), which induces mast cell degranulation and tissue inflammation. Medihoney® (MH) is a medical grade Manuka honey with strong anti-microbial properties. Recent reports also highlight its anti-inflammatory properties through inhibition of histamine release by mast cells.Problem: we investigated the anti-inflammatory effect of MH against neurogenic inflammation by studying its effect on mast cell degranulation induced by SP. LAD-2 human mast cells were activated by SP (1µM) for 40 minutes with or without 30-minute pre-incubation with MH. Degranulation was assessed by the release of the lysosomal enzyme βhexosaminidase (β-hex.). The cells were lysed and the levels of phosphorylation of several protein kinases, involved in the cell signalling pathways underlying mast cell activation, were measured.Outcome: MH (4% and 6%) significantly inhibited mast cell degranulation by approximately 90%. MH (4%) pre-treatment inhibited SP-induced phosphorylation of Akt 1, 2 and 3. 10-DEBC Hydrochloride, a selective Akt inhibitor, significantly inhibited mast cell degranulation in a dose-dependent manner, starting from 87% at a concentration of 30 µM.Learning: intravesical MH could potentially be useful as an anti-inflammatory agent against neurogenic inflammation which might be implicated in the pathology of ICBPS
Real world use of oral treatments in interstitial cystitis/bladder pain syndrome in the UK: Outcome of a cross sectional study
No full textBackground: To describe the oral treatments people living with interstitial cystitis/bladder pain syndrome (IC/BPS) are using to treat their urologic condition in the UK. Method: A questionnaire hyperlink encompassing current and previous medications taken for IC/BPS with other sociodemographic and diagnostic indices was available to the Bladder Health UK website. Interested and fully consented individuals accessed and completed the survey. Results: A total of 601 accessed the questionnaire of whom 173 participants responded (response rate: 28.7%) with a mean ± SD O'Leary/Sant scores of 20.12 ± 9.38. A sample size of 171 was estimated to be used in the survey. A fifth of the participants were not on any treatment at all. Amitriptyline was the most prevalent medication in use both alone and in combination. A shift in the use of unapproved (for IC/BPS) antidepressant, smooth muscle relaxant, opioids, gabapentenoids, and antibiotics was observed in the sample. There were no significant differences between the mean (SD) O'Leary/Sant scores of cohorts currently taking oral medications and those not taking it. More than two-thirds of the participants had been diagnosed with the disease more than 5 years. Just under a half (47.4%) of participants reported a history of allergy. Conclusion: Our study provides contemporary evidence that the treatments used for managing IC/BPS encompass a broad range of medications both recommended and not recommended by current guidelines. The latter suggests patients are willing to try novel treatments when more conventional ones are ineffective.</p
Praziquantel coverage in schools and communities targeted for the elimination of urogenital schistosomiasis in Zanzibar: a cross-sectional survey
No full text© 2015 Knopp et al. Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. The attached file is the published version of the article.NHM Repositor
BAUS 2020 abstracts: P3-6 medical-grade manuka honey inhibits mast cell degranulation by downregulating protein kinase-B (Akt) phosphorylation: potential role as intravesical agent in the treatment of interstitial cystitis/bladder pain syndrome
No full textBackground: mast cells numbers and activity are significantly elevated in several inflammatory conditions including interstitial cystitis (IC/BPS). This condition is associated with the release of neuroactive substances, e.g. substance P (SP), which induces mast cell degranulation and tissue inflammation.Medihoney® (MH) is a medical grade Manuka honey with strong anti-microbial properties. Recent reports also highlight its anti-inflammatory properties through inhibition of histamine release by mast cells.Problem: we investigated the anti-inflammatory effect of MH against neurogenic inflammation by studying its effect on mast cell degranulation induced by SP. LAD-2 human mast cells were activated by SP (1µM) for 40 minutes with or without 30-minute pre-incubation with MH. Degranulation was assessed by the release of the lysosomal enzyme β-hexosaminidase (β-hex.). The cells were lysed and the levels of phosphorylation of several protein kinases, involved in the cell signalling pathways underlying mast cell activation, were measured.Outcome: MH (4% and 6%) significantly inhibited mast cell degranulation by approximately 90%. MH (4%) pre-treatment inhibited SP-induced phosphorylation of Akt 1, 2 and 3. 10-DEBC Hydrochloride, a selective Akt inhibitor, significantly inhibited mast cell degranulation in a dose-dependent manner, starting from 87% at a concentration of 30 µM.Learning: intravesical MH could potentially be useful as an anti-inflammatory agent against neurogenic inflammation which might be implicated in the pathology of ICBPS
- …
